UMB Bank n.a. Has $56,000 Stock Holdings in ResMed Inc. (NYSE:RMD)

UMB Bank n.a. lowered its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 90.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 247 shares of the medical equipment provider's stock after selling 2,218 shares during the quarter. UMB Bank n.a.'s holdings in ResMed were worth $56,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC lifted its position in shares of ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 110 shares during the period. Ashton Thomas Securities LLC acquired a new stake in ResMed during the third quarter worth $34,000. Rosenberg Matthew Hamilton bought a new stake in ResMed in the 4th quarter valued at $54,000. Capital Performance Advisors LLP acquired a new position in shares of ResMed in the 3rd quarter valued at $60,000. Finally, Quarry LP lifted its holdings in shares of ResMed by 271.9% during the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider's stock worth $63,000 after acquiring an additional 242 shares during the period. Institutional investors and hedge funds own 54.98% of the company's stock.

Analyst Ratings Changes

RMD has been the subject of several recent research reports. Stifel Nicolaus started coverage on shares of ResMed in a research report on Friday, December 13th. They issued a "hold" rating and a $250.00 price target for the company. Robert W. Baird boosted their price target on ResMed from $280.00 to $283.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. KeyCorp increased their price objective on ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. The Goldman Sachs Group began coverage on shares of ResMed in a research note on Thursday, January 16th. They issued a "buy" rating on the stock. Finally, Needham & Company LLC reissued a "hold" rating on shares of ResMed in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $233.09.

ResMed Trading Up 0.6 %

RMD stock traded up $1.44 during midday trading on Friday, reaching $250.32. The stock had a trading volume of 778,456 shares, compared to its average volume of 610,125. The firm has a market cap of $36.75 billion, a price-to-earnings ratio of 33.15, a PEG ratio of 1.78 and a beta of 0.70. ResMed Inc. has a twelve month low of $170.56 and a twelve month high of $260.49. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $239.25 and a two-hundred day simple moving average of $234.40.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping analysts' consensus estimates of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the firm posted $1.64 earnings per share. ResMed's revenue for the quarter was up 11.1% compared to the same quarter last year. As a group, research analysts expect that ResMed Inc. will post 9.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 796 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the transaction, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total value of $491,300.00. Following the transaction, the director now owns 81,218 shares of the company's stock, valued at $19,951,201.70. The trade was a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,099 shares of company stock valued at $2,719,385. Company insiders own 0.71% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.